Novel bronchodilators for the treatment of chronic obstructive pulmonary disease
MG Matera, CP Page, M Cazzola - Trends in pharmacological sciences, 2011 - cell.com
Because of the central role of bronchodilators in the treatment of respiratory diseases, there
is still considerable interest in finding novel classes of broncholytic drugs. It can be …
is still considerable interest in finding novel classes of broncholytic drugs. It can be …
Pharmacology and therapeutics of bronchodilators
M Cazzola, CP Page, L Calzetta, MG Matera - Pharmacological Reviews, 2012 - ASPET
Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …
Pharmacology and therapeutics of bronchodilators revisited
MG Matera, CP Page, L Calzetta, P Rogliani… - Pharmacological …, 2020 - ASPET
Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …
An update on bronchodilators in Phase I and II clinical trials
M Cazzola, P Rogliani, A Segreti… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Inhaled bronchodilators are the mainstay of the current management of COPD
at all stages of the disease, and are critical in the symptomatic management of asthma …
at all stages of the disease, and are critical in the symptomatic management of asthma …
Current and novel bronchodilators in respiratory disease
D Spina - Current Opinion in Pulmonary Medicine, 2014 - journals.lww.com
Novel long-acting β 2-agonists (eg indacaterol, vilanterol, olodaterol and carmoterol) and
muscarinic antagonists (eg tiotropium, aclidinium, glycopyrronium and umeclidinium …
muscarinic antagonists (eg tiotropium, aclidinium, glycopyrronium and umeclidinium …
Emerging inhaled bronchodilators: an update
M Cazzola, MG Matera - European Respiratory Journal, 2009 - Eur Respiratory Soc
Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …
pulmonary disease and asthma, and, for this reason and also because the patent protection …
Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends
P Montuschi, G Ciabattoni - Journal of medicinal chemistry, 2015 - ACS Publications
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
Long-acting beta-agonists and their association with inhaled corticosteroids in COPD
L Fuso, N Mores, S Valente, M Malerba… - Current medicinal …, 2013 - ingentaconnect.com
Inhaled bronchodilators, including beta2-agonists and antimuscaric receptor antagonists,
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The …
are the mainstay of pharmacotherapy in chronic obstructive pulmonary disease (COPD). The …
Drugs in clinical development for chronic obstructive pulmonary disease
NA Molfino - Respiration, 2005 - karger.com
Many drugs may be potentially useful in the treatment of chronic obstructive pulmonary
disease (COPD), but relatively few become available for human use due to lack of safety …
disease (COPD), but relatively few become available for human use due to lack of safety …
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
DP Tashkin, LM Fabbri - Respiratory research, 2010 - Springer
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …